Amylyx Pharmaceuticals, Inc. financial data

Symbol
AMLX on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1011% % 108%
Debt-to-equity 12% % -51%
Return On Equity -69% % 19%
Return On Assets -62% % 10%
Operating Margin 23660% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 109,819,569 shares 60%
Common Stock, Shares, Outstanding 109,766,382 shares 60%
Entity Public Float $117,600,000,000 USD 8877%
Common Stock, Value, Issued $11,000 USD 57%
Weighted Average Number of Shares Outstanding, Basic 93,332,930 shares 37%
Weighted Average Number of Shares Outstanding, Diluted 93,332,930 shares 37%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $665,000 USD -100%
Research and Development Expense $92,083,000 USD -27%
Costs and Expenses $156,676,000 USD -67%
Operating Income (Loss) $157,341,000 USD 42%
Nonoperating Income (Expense) $7,424,000 USD -49%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $149,917,000 USD 42%
Income Tax Expense (Benefit) $635,000 USD -132%
Net Income (Loss) Attributable to Parent $149,282,000 USD 42%
Earnings Per Share, Basic -1 USD/shares 53%
Earnings Per Share, Diluted -1 USD/shares 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $225,178,000 USD 213%
Marketable Securities, Current $118,812,000 USD -27%
Accounts Receivable, after Allowance for Credit Loss, Current $132,000 USD -92%
Assets, Current $353,383,000 USD 44%
Property, Plant and Equipment, Net $399,000 USD -68%
Operating Lease, Right-of-Use Asset $5,476,000 USD 7.4%
Other Assets, Noncurrent $2,500,000 USD 419%
Assets $362,741,000 USD 45%
Accounts Payable, Current $5,339,000 USD 259%
Employee-related Liabilities, Current $9,806,000 USD
Accrued Liabilities, Current $19,471,000 USD -61%
Liabilities, Current $25,791,000 USD -52%
Operating Lease, Liability, Noncurrent $4,954,000 USD 733%
Liabilities $30,745,000 USD -44%
Accumulated Other Comprehensive Income (Loss), Net of Tax $815,000 USD 27%
Retained Earnings (Accumulated Deficit) $718,428,000 USD -26%
Stockholders' Equity Attributable to Parent $331,996,000 USD 69%
Liabilities and Equity $362,741,000 USD 45%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $39,824,000 USD -8044%
Net Cash Provided by (Used in) Financing Activities $65,662,000 USD 50024%
Net Cash Provided by (Used in) Investing Activities $43,659,000 USD -5431%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 109,766,382 shares 60%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $17,624,000 USD -5121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $226,161,000 USD 209%
Deferred Tax Assets, Valuation Allowance $158,542,000 USD 89%
Deferred Tax Assets, Gross $159,149,000 USD 86%
Operating Lease, Liability $1,981,000 USD -53%
Depreciation $156,000 USD -50%
Payments to Acquire Property, Plant, and Equipment $11,000 USD -84%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $149,107,000 USD 42%
Lessee, Operating Lease, Liability, to be Paid $2,063,000 USD -55%
Property, Plant and Equipment, Gross $2,320,000 USD -46%
Operating Lease, Liability, Current $981,000 USD -50%
Lessee, Operating Lease, Liability, to be Paid, Year Two $476,000 USD -70%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,587,000 USD -36%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $82,000 USD -73%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,762,000 USD 70%
Operating Lease, Payments $100,000 USD
Deferred Tax Assets, Net of Valuation Allowance $607,000 USD -61%
Share-based Payment Arrangement, Expense $28,000,000 USD -22%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%